Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease  by Friedman, Daniel J. et al.
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 2 3 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 9 . 0 9 7Comparative Effectiveness of CRT-D
Versus Deﬁbrillator Alone in HF Patients
With Moderate-to-Severe
Chronic Kidney Disease
Daniel J. Friedman, MD,* Jagmeet P. Singh, MD, DPHIL,y Jeptha P. Curtis, MD,z W.H. Wilson Tang, MD,x
Haikun Bao, PHD,z Erica S. Spatz, MD, MHS,z Adrian F. Hernandez, MD, MHS,*k Uptal D. Patel, MD,k{
Sana M. Al-Khatib, MD, MHS*kABSTRACTFro
Ge
dio
{D
of
an
NC
Dr
Me
Me
gra
co
gra
Gil
MaBACKGROUND Patients with moderate-to-severe chronic kidney disease (CKD) are poorly represented in clinical trials
of cardiac resynchronization therapy (CRT).
OBJECTIVES This study sought to assess the real-world comparative effectiveness of CRT with deﬁbrillator (CRT-D)
versus implantable cardioverter-deﬁbrillator (ICD) alone in CRT-eligible patients with moderate-to-severe CKD.
METHODS We conducted an inverse probability-weighted analysis of 10,946 CRT-eligible patients (ejection
fraction <35%, QRS >120 ms, New York Heart Association functional class III/IV) with stage 3 to 5 CKD in the National
Cardiovascular Data Registry (NCDR) ICD Registry, comparing outcomes between patients who received CRT-D
(n ¼ 9,525) versus ICD only (n ¼ 1,421). Outcomes were obtained via Medicare claims and censored at 3 years. The
primary endpoint of heart failure (HF) hospitalization or death and the secondary endpoint of death were assessed with
Cox proportional hazards models. HF hospitalization, device explant, and progression to end-stage renal disease were
assessed using Fine-Gray models.
RESULTS After risk adjustment, CRT-D use was associated with a reduction in HF hospitalization or death (hazard ratio
[HR]: 0.84; 95% conﬁdence interval [CI]: 0.78 to 0.91; p < 0.0001), death (HR: 0.85; 95% CI: 0.77 to 0.93;
p < 0.0004), and HF hospitalization alone (subdistribution HR: 0.84; 95% CI: 0.76 to 0.93; p < 0.009). Subgroup
analyses suggested that CRT was associated with a reduced risk of HF hospitalization and death across CKD classes. The
incidence of in-hospital, short-term, and mid-term device-related complications did not vary across CKD stages.
CONCLUSIONS In a nationally representative population of HF and CRT-eligible patients, use of CRT-D was
associated with a signiﬁcantly lower risk of the composite endpoint of HF hospitalization or death among patients
with moderate-to-severe CKD in the setting of acceptable complication rates. (J Am Coll Cardiol 2015;66:2618–29)
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2619AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
CKD = chronic kidney disease
CRT = cardiac
resynchronization therapy
CRT-D = cardiac
resynchronization therapy with
deﬁbrillator
EF = ejection fraction
ESRD = end-stage renal
disease
GFR = glomerular ﬁltration
rateA dvanced symptomatic heart failure (HF) andchronic kidney disease (CKD) are frequentlycomorbid and represent 2 of the most chal-
lenging and costly diseases for individuals, families,
and societies. Approximately 60% of Medicare pa-
tients with HF have stage 3 or greater CKD (1). Annual
HF expenditures in the United States are approxi-
mately $30 billion, and this is expected to rise to $53
billion by 2030 (2). Although improvements in HF
care via pharmacological neurohormonal modulation
have improved longevity and quality of life for the
overall population of HF patients, these therapies
are often contraindicated, poorly tolerated, or of
reduced efﬁcacy among patients with advanced CKD.SEE PAGE 2630
HCC = Hierarchical Condition
Categories
HF = heart failure
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator
ICD-9 = International
Classiﬁcation of Diseases-Ninth
Revision-Clinical Modiﬁcation
LBBB = left bundle branch
block
NYHA = New York Heart
AssociationOver the past decade, cardiac resynchronization
therapy (CRT) has emerged as an important therapy for
patientswith a prolongedQRS andmoderate-to-severe
medication-refractory systolic HF. Multiple large ran-
domized trials have demonstrated that CRT can reduce
HF symptoms, HF hospitalizations, and death (3–6).
These landmark studies either excluded or did not
report outcomes among patients with advanced
(stages 3b to 5) CKD (7). Data on CRT in advanced CKD
are currently limited to small, retrospective, single-
center studies (8,9) and a single meta-analysis (10).
Concerns regarding the potential for decreased CRT
efﬁcacy and increased complications may lower the
rate of CRT use in patients with advanced CKD. Thus,
optimal device strategy for this population remains
unclear (11) and variability in practice exists (12).
To address this important gap in knowledge, we
performed an observational comparative effectiveness
analysis comparing outcomes among CRT-eligible
patients who received a CRT with implantable
cardioverter-deﬁbrillator (ICD) versus ICD alone in
the National Cardiovascular Data Registry (NCDR)
ICD Registry. We hypothesized that CRT would be
associated with a lower risk in HF hospitalizations
and death, but the magnitude of effect may be atten-
uated based on severity of CKD.
METHODS
DATA SOURCES. NCDR ICD Regist ry . Patients for
this study were selected from the NCDR ICD Registry,
a national registry that included approximately
90% of all ICD implantations in the United States (13).
All Medicare beneﬁciaries receiving a primary pre-
vention ICD are enrolled in the ICD registry according
to a mandate from the Centers for Medicare &
Medicaid Services. The ICD registry includes exten-
sive information on baseline patient characteristicsand in-hospital outcomes. Rigorous data
abstraction processes and standards have
been published and include electronic data
submission via a secure website, standard-
ized variable deﬁnitions, electronic quality
checks, and annual on-site audits of 10% of
enrolling sites (14). This approach has led to
>90% accuracy for data elements (15).
Medicare database . Longitudinal outcomes
were obtained by linking fee-for-service
Medicare claims to the ICD registry using a
previously validated methodology (16) with
indirect identiﬁers: hospital, patient sex,
birth date, admission date, and discharge
date. Inpatient claims, outpatient claims, and
the denominator ﬁles were used to assess
morbidity and mortality. We used the Chronic
Conditions Warehouse database (years 2005
to 2011), which includes both Part A and
Part B Medicare claims to assess speciﬁc
covariates and outcomes.
STUDY POPULATION. We restricted the study
population to all fee-for-service Medicare
patients $65 years old with stage 3 to
5 CKD (glomerular ﬁltration rate [GFR]
<60 ml/min/1.73 m2, including those on dial-
ysis) who underwent ICD implantation (with or
without CRT) between January 1, 2006, and December
31, 2009; were eligible for CRT based on contemporary
indications during the study period (ejection fraction
[EF] <35%, QRS >120 ms, New York Heart Association
[NYHA] functional class III/IV); and could be linked to
Medicare claims data. We excluded patients who were
admitted during a non-elective hospitalization, were
enrolled in the ICD registry at the time of generator
change, required an epicardial lead, or had a prior
pacemaker or deﬁbrillator.
PATIENT CHARACTERISTICS. All baseline character-
istics except for the frailty and dementia variables
were directly obtained from the ICD registry case
report form. Dementia was deﬁned by the presence of
a diagnosis from either of 2 Hierarchical Condition
Categories (HCCs): “dementia” or “senility, nonpsy-
chotic organic brain syndromes/conditions.” Frailty/
disability was deﬁned by the following HCCs:
protein–calorie malnutrition; quadriplegia, other
extensive paralysis; paraplegia; spinal cord disorders/
injuries; hemiplegia/hemiparesis; legally blind; de-
cubitus ulcer of skin; chronic ulcer of skin, except
decubitus; vertebral fractures; amputation status,
lower limb amputation; and amputation status, upper
limb. Missing variables were addressed with the
multiple imputation technique; the coefﬁcients of
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ﬁnal estimates for the models.
GFR was calculated using the Modiﬁcation of
Diet in Renal Disease formula (17). For subgroup an-
alyses, patients were divided based on CKD stage:
3a (GFR 45 to 59 ml/min/1.73 m2), 3b (GFR 30 to
44 ml/min/1.73 m2), 4 (GFR 15 to 29 ml/min/1.73 m2),
and 5 (GFR <15 ml/min/1.73 m2 or on dialysis).
TREATMENT. The treatment of interest was CRT with
ICD (CRT-D) versus ICD alone as deﬁned by the ICD
registry.
OUTCOMES. The primary outcome was the compos-
ite endpoint of HF hospitalization or death. Second-
ary outcomes included HF hospitalization, death,
progression to end-stage renal disease (ESRD),
device explant, and in-hospital and short-term
out-of-hospital complications. Follow-up was
censored 3 years after device implant or on the date at
which the patient’s data were no longer available
(due to death or transition to a managed care plan).
Vital status was determined by the Medicare
denominator ﬁle. Longitudinal outcomes were
determined by International Classiﬁcation of Dis-
eases-Ninth Revision-Clinical Modiﬁcation (ICD-9)-
CM, Current Procedural Terminology (CPT) codes, or
diagnosis related group (DRG) codes as appropriate:
HF hospitalization (DRG 127 before October 1, 2007,
and DRGs 291 to 293 on or after October 1, 2007);
device explant (both CPT 33241 and 33244). Incident
transition to ESRD was deﬁned by the ﬁrst occurrence
of any ICD-9 code in the HCC “dialysis status” or
selected ICD-9 codes from HCC “renal failure”: 99656,
99656, 99673, V451, V4511, V4512, V560, V561, V562,
V5631, V5632, V568, 40301, 40311, 40311, 40391,
40402, 40403, 40412, 40413, 40492, 40493, 5855, and
5856. Post-discharge complications included hemo-
thorax or pneumothorax (ICD-9 codes 512.1, 511.8,
511.89), hematoma (ICD-9 code 998.1x), cardiac tam-
ponade or pericardial effusion requiring peri-
cardiocentesis (ICD-9 codes 420.x, 423.0, 423.3, or
423.9, or ICD-9 procedure codes 37.0 or 37.12), me-
chanical complications requiring system revision
(ICD-9 codes 996.04 or 996.01 combined with ICD-9
procedure codes 37.75, 37.79, 37.97, 37.99, or 00.52),
and device-related infection (ICD-9 code 996.61).
STATISTICAL ANALYSIS. Baseline characteristics of
the study population by treatment group are
described using proportions for categorical variables
and means with standard deviations for continuous
variables. Differences between groups were tested
using the chi-square test for categorical variables and
Student t tests for continuous variables.We reported observed event rates by treatment
group. For the primary endpoint of HF hospitaliza-
tion or death and the secondary endpoint of death,
we used the Kaplan-Meier methods to calculate
event rates and log-rank test to assess differences
between groups. For HF hospitalization, progression
to ESRD, and device explant, we utilized the cumu-
lative incidence function to calculate event rates and
Gray tests to assess differences between groups. The
cumulative incidence function accounts for the
competing risk of mortality, which is high in this
population.
To estimate the risk-adjusted association between
CRT-D and each outcome, we employed inverse
probability-weighted Cox proportional hazard or
Fine-Gray models. We used logistic regression models
to predict CRT-D use deriving an inverse probability
weight based on the following covariates: age, sex,
race, ethnicity, QRS duration, QRS morphology, car-
diomyopathy etiology, atrial ﬁbrillation or ﬂutter,
history of sustained ventricular arrhythmia, EF,
NYHA symptom class, prior percutaneous coronary
intervention, prior coronary artery bypass grafting,
prior valve surgery, medication use (beta-blockers,
aldosterone antagonists, angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers,
aspirin, statin, clopidogrel, ticlopidine, hydralazine,
long-acting nitrate, amiodarone, warfarin, digoxin,
diuretic), diabetes, prior myocardial infarction, sinus
node dysfunction, chronic lung disease, cerebrovas-
cular disease, systolic blood pressure, creatinine,
blood urea nitrogen, dialysis dependence, serum so-
dium, prior cardiac arrest, hypertension, syncope, HF
duration, atrioventricular conduction, CKD stage,
implanting operator training, implanting operator
volume, geographic region, teaching versus non-
teaching hospital, hospital size, implant year,
dementia, electrophysiology laboratory presence in
hospital, and disability/frailty. The differences
between these characteristics in the weighted ICD
and CRT-D groups were examined by calculating
absolute standardized differences. Small standard-
ized differences (<10%) indicate that the baseline
covariates among patients in the CRT-D and ICD alone
groups are balanced.
Falsiﬁcation endpoints (18) (gastrointestinal bleed
[ICD-9 code 578] and bone disorder/fracture [ICD-9
codes 730 to 736, 802 to 824]) were chosen to test
the adequacy of our statistical model because these
outcomes should not vary based on the receipt of
CRT-D versus ICD.
We subsequently assessed for an interaction
between baseline characteristics (including CKD
class) and the association between CRT-D and
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ment for all covariates in models; we adjusted for
CKD in all models where CKD class was not the
variable of interest. We reported hazard ratios (HR)
or subdistribution HR and their 95% conﬁdence in-
tervals (CIs) based on robust sandwich variance es-
timates to account for clustering of patients within
hospitals. A p value of <0.05 was considered statis-
tically signiﬁcant for all tests. Analyses were per-
formed using SAS (version 9.3, SAS institute, Cary,
North Carolina).
RESULTS
Between January 1, 2006, and December 31, 2009,
60,299 individuals with an EF <35% and QRS >120 ms
underwent new ICD implantation and were enrolled
in the registry; 64% (n ¼ 38,274) of these individuals
had stage 3 CKD or greater. We excluded individuals
with mildly symptomatic HF (NYHA functional class
I/II; n ¼ 10,087), a prior pacemaker (n ¼ 8,464), those
implanted during a nonelective hospitalization
(n ¼ 8,466), and those who required an epicardial LV
lead (n ¼ 311), resulting in a total study population of
10,947. Median follow-up was 30 months. Baseline
patient, hospital, operator, and procedure character-
istics associated with receipt of CRT-D versus ICD are
detailed in Table 1.
Logistic regression analyses (Online Table 1)
demonstrate that receipt of CRT-D (vs. ICD) was
more common among those with left bundle branch
block (LBBB), longer QRS durations, having an elec-
trophysiologist as the implanting physician, and
higher volume of CRT implants at the hospital and
physician level. CRT-D implantation was less com-
mon among those with atrial ﬁbrillation or ﬂutter,
absence of a prior history of ventricular tachycardia,
non-white race, and among those implanted early in
the study period. There was no relationship between
CKD stage, age, or sex, and likelihood of receiving a
CRT-D versus ICD.
We assessed rates of in-hospital, 30-day, and
90-day complication rates across CKD subgroups.
There was no signiﬁcant difference in total in-
hospital, 30-day, or 90-day complications among
CRT-D or ICD recipients across CKD subgroups
(Table 2). CRT-D implantation (vs. ICD alone) was not
associated with an increased risk of in-hospital,
30-day, or 90-day complications.
Among all CRT eligible individuals, CRT-D use was
associated with a lower 3-year incidence of HF
hospitalization or death (57% vs. 45%; p < 0.001)
(Figure 1A), death (40% vs. 31%; p < 0.001) (Figure 1B),
HF hospitalization (37% vs. 29%; p < 0.001) (Figure 1C),but not progression to ESRD (CKD stages 3 and 4
only [n ¼ 10,348]; 8% vs. 7%; p ¼ 0.20) (Figure 1D) in
unadjusted analyses. There were no differences in
the rates of device explant or the falsiﬁcation end-
points of gastrointestinal bleed and bone disorder/
fracture. See Table 3 for a complete display of unad-
justed 3-year incidence rates and unadjusted models
describing the relation between CRT-D (vs. ICD) and
outcomes.
In inverse probability-weighted models, CRT-D use
was associated with a signiﬁcantly lower risk of HF
hospitalization or death (HR: 0.82; 95% CI: 0.75 to
0.90; p < 0.0001), death (HR: 0.84; 95% CI: 0.76 to
0.94; p ¼ 0.0019), and HF hospitalization (sub-
distribution HR: 0.81; 95% CI: 0.72 to 0.91;
p ¼ 0.0003), but not device explant, transition to
ESRD (among CKD stages 3 and 4), or falsiﬁcation
endpoints (Table 3). Notably, the cohorts resulting
from the inverse probability-weighted estimators
analyses were well balanced with regard to baseline
patient characteristics, demonstrating adequate sta-
tistical adjustment for all measured baseline charac-
teristics (Online Table 2).
Subgroup analyses by CKD class demonstrated
there were no signiﬁcant interactions between treat-
ment (CRT-D vs. ICD) and CKD class and the outcomes
of HF hospitalization or death (p ¼ 0.15), HF hospi-
talization (p ¼ 0.13), and death (p ¼ 0.69) (Central
Illustration, Online Figure 1 for the associated
unadjusted analyses).
We performed multivariable-adjusted subgroup
analyses to assess for the presence of an interaction
between device type, key baseline characteristics,
and the primary outcome of HF hospitalization or
death (Figure 2, Online Figure 2 for the associated
unadjusted analyses). We noted no signiﬁcant inter-
action between key baseline characteristics, device
type, and outcomes, except for QRS morphology. We
found a signiﬁcant interaction between LBBB versus
non-LBBB QRS morphology, device type, and the
primary outcome (pinteraction ¼ 0.0005), and subgroup
analyses suggested that the lower risk of HF hospi-
talization or death occurred exclusively in the LBBB
population (LBBB: 0.73, 95% CI: 0.66 to 0.81;
p < 0.0001 vs. non-LBBB: 0.97, 95% CI: 0.86 to 1.09;
p ¼ 0.58). In an exploratory analysis, we found no
interaction (pinteraction ¼ 0.67) between QRS
morphology, device type, and transition to ESRD.
When subgroup analyses by CKD stage were per-
formed in the LBBB-only population (Online Table 3),
we found results similar to those found in the overall
population (Central Illustration). There was no inter-
action between QRS duration, device type, and
outcome.
TABLE 1 Baseline Patient, Hospital, Operator, and
Procedure Characteristics
ICD
(n ¼ 1,421)
CRT-D
(n ¼ 9,525) p Value
Age, yrs 75.9  6.1 75.7  6.1 0.22
Sex
Male 1,013 (71.3) 6,229 (65.4) <0.0001
Female 408 (28.7) 3,296 (34.6)
Race
White non-Hispanic 1,217 (85.6) 8,464 (88.9) 0.0007
Black non-Hispanic 113 (8.0) 566 (5.9)
Hispanic 64 (4.5) 296 (3.1)
Other 27 (1.9) 199 (2.1)
QRS duration, ms
120–129 244 (17.2) 740 (7.8) <0.0001
130–139 258 (18.2) 1,426 (15.0)
140–149 245 (17.2) 1,751 (18.4)
150–159 218 (15.3) 1,726 (18.1)
160–169 205 (14.4) 1,739 (18.3)
$170 251 (17.7) 2,143 (22.5)
Intraventricular conduction
Missing 1 (0.1) 8 (0.1) <0.0001
Abnormal—LBBB 745 (52.4) 7,016 (73.7)
Abnormal—other 675 (47.5) 2,501 (26.3)
Non-ischemic
cardiomyopathy
Missing 0 (0.0) 2 (0.0) <0.0001
No 1,074 (75.6) 6,240 (65.5)
Yes—within the past
9 months
103 (7.2) 904 (9.5)
Yes—>9 months 244 (17.2) 2,379 (25.0)
Ischemic heart disease 1,101 (77.5) 6,475 (68.0) <0.0001
Atrial ﬁbrillation/atrial ﬂutter 559 (39.3) 3,164 (33.2) <0.0001
Ventricular tachycardia 308 (21.7) 1,643 (17.2) 0.0002
NYHA functional class
III 1,348 (94.9) 9,046 (95.0) 0.86
IV 73 (5.1) 479 (5.0)
Previous PCI 455 (32.0) 3,011 (31.6) 0.95
Previous CABG 719 (50.6) 3,968 (41.7) <0.0001
Previous valvular surgery 123 (8.7) 792 (8.3) 0.70
Diabetes 626 (44.1) 4,060 (42.6) 0.56
Previous myocardial
infarction
856 (60.2) 5,047 (53.0) <0.0001
Sinus node function
Missing 1 (0.1) 5 (0.1) <0.0001
Normal 991 (69.7) 7,177 (75.3)
Abnormal 429 (30.2) 2,343 (24.6)
Chronic lung disease 350 (24.6) 2,335 (24.5) 0.92
Cerebrovascular disease 287 (20.2) 1,557 (16.3) 0.0013
Cardiac arrest 35 (2.5) 163 (1.7) 0.12
Hypertension 1,154 (81.2) 7,570 (79.5) 0.17
Syncope 170 (12.0) 928 (9.7) 0.0318
CHF duration
Missing 0 (0.0) 2 (0.0) <0.0001
No 98 (6.9) 213 (2.2)
<9 months 347 (24.4) 2,328 (24.4)
>9 months 976 (68.7) 6,982 (73.3)
Continued in the next column
TABLE 1 Continued
ICD
(n ¼ 1,421)
CRT-D
(n ¼ 9,525) p Value
AV conduction
Missing 5 (0.4) 33 (0.3) 0.14
Normal 937 (65.9) 6,572 (69.0)
First degree heart block 432 (30.4) 2,621 (27.5)
Second or third degree
(not paced)
47 (3.3) 299 (3.1)
EF, % 23.8 (5.7) 23.3 (5.8) 0.0024
CKD stage
3a 698 (49.1) 4,721 (49.6) 0.0004
3b 444 (31.2) 3,171 (33.3)
4 168 (11.8) 1,146 (12.0)
5 111 (7.8) 487 (5.1)
Dialysis 100 (7.0) 417 (4.4) <0.0001
BUN level, mg/dl
Missing 2 (0.1) 11 (0.1) 0.0331
#20 245 (17.2) 1,962 (20.6)
20–40 869 (61.2) 5,607 (58.9)
>40 305 (21.5) 1,945 (20.4)
Sodium level, mEq/l
Missing 4 (0.3) 30 (0.3) 0.55
#135 204 (14.4) 1,291 (13.6)
135–145 1,187 (83.5) 8,067 (84.7)
>145 26 (1.8) 137 (1.4)
Systolic BP, mm Hg
Missing 12 (0.8) 41 (0.4) 0.10
#100 90 (6.3) 653 (6.9)
100–130 603 (42.4) 4,184 (43.9)
>130 716 (50.4) 4,647 (48.8)
Angiotensin-converting
enzyme inhibitor
827 (58.2) 5,367 (56.3) 0.19
Amiodarone 194 (13.7) 1,148 (12.1) 0.09
Hydralazine 81 (5.7) 494 (5.2) 0.42
Angiotensin receptor
blocker
259 (18.2) 2,048 (21.5) 0.0048
Aspirin 948 (66.7) 6,383 (67.0) 0.82
Beta-blocker 1,200 (84.4) 8,217 (86.3) 0.06
Warfarin 423 (29.8) 2,646 (27.8) 0.12
Digoxin 379 (26.7) 2,648 (27.8) 0.37
Diuretic 1,105 (77.8) 7,574 (79.5) 0.13
Long-acting nitrate 193 (13.6) 1,354 (14.2) 0.52
Clopidogrel 337 (23.7) 2,150 (22.6) 0.34
Ticlopidine 9 (0.6) 36 (0.4) 0.16
Statin 952 (67.0) 6,268 (65.8) 0.38
Dementia 45 (3.2) 289 (3.0) 0.79
Disability/frailty 131 (9.2) 704 (7.4) 0.0155
EP operator ICD training
Unknown 411 (28.9) 2,368 (24.9) <0.0001
Board-certiﬁed
EP/EP fellowship
703 (49.5) 5,850 (61.4)
Surgeon 23 (1.6) 70 (0.7)
Other 284 (20.0) 1,237 (13.0)
Operator CRT volume
#20 implants/year 986 (69.4) 4,841 (50.8) <0.0001
>20 implants/year 435 (30.6) 4,684 (49.2)
Continued on the next page
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TABLE 1 Continued
ICD
(n ¼ 1,421)
CRT-D
(n ¼ 9,525) p Value
Region
Other 54 (3.8) 278 (2.9) 0.17
New England 55 (3.9) 408 (4.3)
Atlantic 477 (33.6) 3,171 (33.3)
Central 680 (47.9) 4,465 (46.9)
Mountain 55 (3.9) 380 (4.0)
Paciﬁc 100 (7.0) 823 (8.6)
Teaching status
Unknown 53 (3.7) 278 (2.9) 0.21
Council of teaching
hospitals
386 (27.2) 2,742 (28.8)
Teaching hospital 385 (27.1) 2,635 (27.7)
Not teaching hospital 597 (42.0) 3,870 (40.6)
Center CRT volume
#20 implants/yr 324 (22.8) 1,059 (11.1) <0.0001
>20 implants/yr 1,097 (77.2) 8,466 (88.9)
Beds set up and staffed
Unknown 53 (3.7) 278 (2.9) 0.0011
#100 70 (4.9) 532 (5.6)
101–500 883 (62.1) 5,488 (57.6)
>500 415 (29.2) 3,227 (33.9)
Implant year
2006 383 (27.0) 2,149 (22.6) <0.0001
2007 384 (27.0) 2,362 (24.8)
2008 366 (25.8) 2,544 (26.7)
2009 288 (20.3) 2,470 (25.9)
EP lab present in hospital 994 (70.0) 6,671 (70.0) 0.95
Values are mean  SD or n (%).
AV ¼ atrioventricular; BP ¼ blood pressure; BUN¼ blood urea nitrogen; CABG ¼
coronary artery bypass graft; CHF ¼ congestive heart failure; CKD¼ chronic kidney
disease; CRT ¼ cardiac resynchronization therapy; CRT-D ¼ cardiac resynchroni-
zation therapy with deﬁbrillator; EF ¼ ejection fraction; EP ¼ electrophysiologist/
electrophysiology; ICD ¼ implantable cardioverter-deﬁbrillator; LBBB ¼ left
bundle branch block; NYHA ¼ New York Heart Association; PCI ¼ percutaneous
coronary intervention.
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2623DISCUSSION
In this observational study of CRT-eligible in-
dividuals with stages 3 to 5 CKD, we demonstrated
that CRT-D use was associated with a signiﬁcantly
lower risk of HF hospitalization or death, death, and
HF hospitalization. Subgroup analyses demonstrated
no interaction between treatment (CRT-D vs. ICD)
and CKD class and death or HF hospitalization. In
the setting of nonsigniﬁcant interaction terms, it
appears that the absence of an association (based on
point estimates) between CRT-D receipt and lower
risk of death among CKD stage 5 patients and a
lower risk of HF hospitalizations among CKD V
and IV patients is related to insufﬁcient power
(Online Table 4). There was no association between
CRT-D use and progression to ESRD (among CKD
stages 3 and 4) and device explant. In-hospital,short-term, and mid-term complications associated
with CRT implantation do not appear to vary based
on CKD stage. Notably, a signiﬁcant association be-
tween CRT-D use and lower risk of the primary
outcome (HF hospitalization or death) was observed
exclusively in LBBB patients. Otherwise, the associ-
ation between CRT-D use and outcomes did not vary
based on key baseline characteristics: age, sex,
NYHA functional class, CKD class, ejection fraction,
QRS duration, cardiomyopathy etiology, diabetes, or
atrial ﬁbrillation or ﬂutter. To date, this represents
the largest study of patients with advanced CKD
undergoing CRT and supports the use of CRT inde-
pendent of renal function.
IN THE CONTEXT OF THE CURRENT LITERATURE.
Although retrospective analyses of landmark CRT
trials have shown an association between CRT
and improved outcomes in patients with mild-to-
moderate CKD, until now, analyses of patients
with more advanced (stages 3b to 5) CKD have been
limited to small, single-center studies and a single
meta-analysis. In a pre-speciﬁed analysis of the
CARE-HF study (Cardiac Resynchronization—Heart
Failure Study), CRT was associated with a similar
reduction in death or cardiovascular hospitalization
among individuals with a GFR <60 ml/min/1.73 m2
and those with a GFR >60 ml/min/1.73 m2 (4).
Similarly, a subgroup analysis of the RAFT trial
(Resynchronization/Deﬁbrillation for Ambulatory
Heart Failure Trial) (which included NYHA functional
class II/III patients) demonstrated that the favorable
impact of CRT did not vary based on a GFR threshold
of 60 ml/min/1.73 m2 (6). A secondary analysis of the
REVERSE (Resynchronization Reverses Remodeling
in Systolic Left Ventricular Dysfunction) study
(which included NYHA functional class I/II patients)
demonstrated that although echocardiographic re-
sponse was worsened among individuals with a
GFR <60.3 ml/min/1.73 m2, the risk reduction asso-
ciated with CRT did not vary based on this
GFR threshold (19). It is important to note that
these landmark trials either formally excluded or
did not report enrollment of patients with more
advanced CKD.
Although the few retrospective studies that exist
suggest that CRT may have a role in advanced CKD
(8,10,20), these studies have been small, single-
centered, and often without a control group. Not
surprisingly, a recent authoritative review on the
evidence for HF therapies in CKD concluded that
although there are data to support the use of CRT in
CKD stage 3, there are no speciﬁc data to guide its use
in CKD stages 4 and 5 (11). Importantly, the results
TABLE 2 Complications Associated With CRT-D and ICD Implantation Across CKD Stages
Device
All (CKD Stages 3–5)
(n ¼ 10,946)
CKD Stage 3a
(n ¼ 5,419)
CKD Stage 3b
(n ¼ 3,615)
CKD Stage 4
(n ¼ 1,314)
CKD Stage 5
(n ¼ 598) ptrend* pinteraction†
In-hospital complications
Any ICD 82 (5.8) 36 (5.2) 29 (6.5) 9 (5.4) 8 (7.2) 0.70 0.51
CRT 571 (6.0) 278 (5.9) 197 (6.2) 74 (6.5) 22 (4.5) 0.44
Death ICD 2 (0.1) 1 (0.1) 0 (0.0) 1 (0.6) 0 (0.0) 0.45 0.75
CRT 23 (0.2) 9 (0.2) 6 (0.2) 6 (0.5) 2 (0.4) 0.13
Hematoma ICD 33 (2.3) 15 (2.1) 15 (3.4) 1 (0.6) 2 (1.8) 0.22 0.23
CRT 239 (2.5) 111 (2.4) 84 (2.6) 35 (3.1) 9 (1.8) 0.39
Pneumothorax or hemothorax ICD 15 (1.1) 6 (0.9) 6 (1.4) 2 (1.2) 1 (0.9) 0.86 0.54
CRT 90 (0.9) 53 (1.1) 23 (0.7) 10 (0.9) 4 (0.8) 0.34
Cardiac tamponade or pericardial
effusion requiring
pericardiocentesis
ICD 13 (0.9) 8 (1.1) 1 (0.2) 2 (1.2) 2 (1.8) 0.15 0.10
CRT 58 (0.6) 27 (0.6) 23 (0.7) 7 (0.6) 1 (0.2) 0.55
30-day complications
Any 30-day complication‡ ICD 67 (4.7) 31 (4.4) 23 (5.2) 7 (4.2) 6 (5.4) 0.63 0.57
CRT 474 (5.0) 234 (5.0) 160 (5.0) 64 (5.6) 16 (3.3) 0.28
Hematoma ICD 43 (3.0) 20 (2.9) 17 (3.8) 3 (1.8) 3 (2.7) 0.58 0.53
CRT 302 (3.2) 139 (2.9) 106 (3.3) 45 (3.9) 12 (2.5) 0.26
Pneumothorax or hemothorax ICD 17 (1.2) 7 (1.0) 7 (1.6) 2 (1.2) 1 (0.9) 0.85 0.51
CRT 104 (1.1) 61 (1.3) 27 (0.9) 12 (1.0) 4 (0.8) 0.28
Cardiac tamponade or pericardial
effusion requiring
pericardiocentesis
ICD 16 (1.1) 8 (1.1) 2 (0.5) 4 (2.4) 2 (1.8) 0.12 0.07
CRT 87 (0.9) 43 (0.9) 32 (1.0) 11 (1.0) 1 (0.2) 0.38
90-day complications
Any 90-day complication§ ICD 5 (0.4) 3 (0.4) 2 (0.5) 0 (0.0) 0 (0.0) 1.00 0.84
CRT 31 (0.3) 16 (0.3) 11 (0.3) 3 (0.3) 1 (0.2) 1.00
Mechanical complications requiring
a system revision
ICD 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) n/a n/a
CRT 1 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1.00
Device-related infection ICD 5 (0.4) 3 (0.4) 2 (0.5) 0 (0.0) 0 (0.0) 1.00 0.84
CRT 31 (0.3) 16 (0.3) 11 (0.3) 3 (0.3) 1 (0.2) 1.00
Values are n (%). *Trend across CKD stages, within designated device category. †Between device type and outcome, within the overall population. ‡Hematoma, pneumothorax,
and tamponade or pericardial effusion requiring pericardiocentesis. §Mechanical complications, device infection.
Abbreviations as in Table 1.
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2624from the current study corroborate the observed as-
sociation between CRT and improved outcomes
in stage 3 CKD and, importantly, demonstrate the
extension of these beneﬁts to the population of
patients with stages 4 and 5 CKD.
Prior analyses of CRT in CKD have demonstrated
that CRT may have the potential to improve renal
function (8,21,22). Although the potential improve-
ment in GFR as assessed by a recent meta-analysis
appears to be small (w2.3 ml/min/1.73 m2), a signiﬁ-
cant minority may experience improvements sufﬁ-
cient to reclassify the CKD stage (10). Furthermore,
some studies have suggested that as CKD increases in
severity, the likelihood of an appreciable improve-
ment in GFR increases (8,21). On the basis of these
data, we hypothesized that CRT may have the
potential to reduce the transition to ESRD amongstage 3 and 4 CKD patients. In our study, we found no
relationship between treatment type and progression
to ESRD. There are many potential reasons for this
ﬁnding. First, it is possible that CRT-induced changes
in cardiorenal physiology are simply too incremental
or not sufﬁciently sustained to inﬂuence a hard
endpoint such as transition to ESRD. It is also possible
that patients with stage 3 and 4 CKD are too far along
in the process of renal deterioration to experience
CRT-induced reduction in the risk of progression to
ESRD. It is also possible that a lack of statistical power
or insufﬁcient follow-up precluded our ability to
detect an existing relationship between CRT and a
reduction in progression to ESRD. Notably, it remains
possible that individuals with a milder degree of renal
impairment may experience delayed or reduced pro-
gression to ESRD.
FIGURE 1 Rates of HF Hospitalization or Death, Death, HF Hospitalization, and Progression to ESRD Among Patients With CRT-D Versus ICD Alone
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Kaplan-Meier curves are shown for heart failure (HF) hospitalization or death (A) and death (B). Cumulative incidence functions accounting for the competing risks of
death for HF hospitalization (C) and progression to end-stage renal disease (ESRD) (D) are shown. CI ¼ conﬁdence interval; CRT ¼ cardiac resynchronization therapy;
CRT-D ¼ cardiac resynchronization therapy with deﬁbrillator; HR ¼ hazard ratio; ICD ¼ implantable cardioverter-deﬁbrillator.
TABLE 3 Unadjusted 3-Year Event Rates and Unadjusted and Adjusted Analyses Comparing Outcomes Among CRT-D and ICD Recipients
Outcomes
Unadjusted 3-Year Event Rates Unadjusted Adjusted*
ICD
(n ¼ 1,421)
CRT-D
(n ¼ 9,525)
HR or Subdistribution
HR (95% CI) for
CRT-D vs. ICD p Value
HR or Subdistribution
HR (95% CI) for
CRT-D vs. ICD p Value
HF hospitalization
or death†
813 (57.2) 4,282 (45.0) 0.72 (0.67–0.78) <0.0001 0.82 (0.75–0.90) <0.0001
Death† 569 (40.0) 2,936 (30.8) 0.73 (0.67–0.80) <0.0001 0.84 (0.76–0.94) 0.0019
HF hospitalization‡ 529 (37.2) 2,722 (28.6) 0.73 (0.67–0.80) <0.0001 0.81 (0.72–0.91) 0.0003
ESRD‡§ 105 (8.0) 637 (7.0) 0.88 (0.72–1.07) 0.19 1.01 (0.79–1.29) 0.97
Device explant‡ 4 (0.3) 19 (0.2) 0.72 (0.24–2.12) 0.54 0.64 (0.16–2.60) 0.53
Gastrointestinal bleed‡ 169 (11.9) 1,121 (11.8) 0.99 (0.84–1.17) 0.92 1.11 (0.91–1.36) 0.30
Bone disorder/fracture‡ 373 (26.2) 2,448 (25.7) 0.98 (0.88–1.09) 0.66 0.92 (0.80–1.04) 0.19
Values are n (%) unless otherwise noted. *Adjusted using inverse probability-weighted Cox proportional hazard or Fine-Gray models, as appropriate. †Hazard ratio. ‡Sub-
distribution hazard ratio. §For 10,348 pre-ESRD patients, including 9,038 CRT patients.
CI ¼ conﬁdence interval; ESRD ¼ end-stage renal disease; HF ¼ heart failure; HR ¼ hazard ratio; other abbreviations as in Table 1.
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CENTRAL ILLUSTRATION CRT-D Versus ICD in Patients With Advanced CKD: Outcomes by CKD Stage
0.5         1.0         1.5         2.0
 CRT Better  ICD Better      
Friedman, D.J. et al. J Am Coll Cardiol. 2015; 66(23):2618–29.
Hazard ratios (HR) were calculated for the endpoints of heart failure (HF) hospitalization or death and death. Subdistribution HR were calculated for
the endpoints of HF hospitalization and transition to end-stage renal disease (ESRD). Conﬁdence intervals (CI) are presented with each point estimate.
CKD ¼ chronic kidney disease; CRT ¼ cardiac resynchronization therapy; CRT-D ¼ cardiac resynchronization therapy with deﬁbrillator; ICD ¼ implantable
cardioverter-deﬁbrillator.
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2626Prior studies have suggested that more severe
renal dysfunction was associated with increased
risk of device-related complications (23–25). These
reports of increased complications may have inﬂu-
enced the reduced rates of CRT utilization among
individuals with advanced CKD. In our study,
we demonstrated that among CRT-D recipients,
progressive CKD was not associated with an overall
increased risk of in-hospital, 30-day, or 90-day
complications.
STUDY LIMITATIONS. First, treatment was not ran-
domized, and although we utilized sophisticated
statistical methods to account for differences be-
tween treatment groups, we cannot rule out the
potential for residual confounding. The ICD Registry
does not include information on cardiac structureand function (except for EF), and thus we cannot
exclude the possibility that differences in chamber
size, valvular disease, dyssynchrony, and so on may
have inﬂuenced device selection and outcomes. We
do note that the lack of association between treat-
ment group and the falsiﬁcation endpoints and the
well-balanced characteristics among the treatment
groups in the cohorts resulting from the inverse
probability-weighted estimator analyses suggest that
statistical techniques were adequate. Our study pop-
ulation was limited to adults $65 years of age with
fee-for-service Medicare, and thus, the results may
not be generalizable to younger individuals. In
contrast to randomized trials of CRT, we did not have
access to echocardiographic data, and this study did
not include patient-centered outcomes, including
FIGURE 2 Forest Plot Depicting Multivariable-Adjusted Subgroup Analyses
Subgroup HR (95%CI) P value ICD Group CRT Group
Age
     <75 Yr
     >=75 Yr
Sex
     Male
     Female
NYHA class
     III
     IV
Ischemic Cardiomyopathy
     No
     Yes
Ejection Fraction
     <25%
     >=25%
QRS Duration
     < 150ms
     >= 150ms
Bundle Branch Morphology
     Non–LBBB
     LBBB
Diabetes
     No
     Yes
Atrial Fibrillation/Flutter
     No
     Yes
0.85 (0.74-0.97)
0.84 (0.76-0.93)
0.87 (0.79-0.96)
0.75 (0.65-0.88)
0.84 (0.77-0.91)
0.94 (0.65-1.36)
0.79 (0.66-0.93)
0.86 (0.78-0.94)
0.80 (0.71-0.90)
0.88 (0.79-0.98)
0.86 (0.77-0.97)
0.81 (0.72-0.91)
0.97 (0.86-1.09)
0.73 (0.66-0.81)
0.82 (0.73-0.91)
0.88 (0.78-0.99)
0.89 (0.80-0.99)
0.80 (0.70-0.91)
0.942
0.114
0.528
0.359
0.227
0.523
0.001
0.387
0.224
327
486
593
220
769
44
180
633
377
436
439
374
407
406
132
381
460
353
595
826
1013
408
1348
73
347
1074
597
824
747
674
675
746
795
626
862
559
55
58.8
58.5
53.9
57.1
60.3
51.9
58.9
63.2
52.9
58.8
54.5
60.3
54.4
54.3
60.9
53.4
63.2
1713
2569
2997
1285
3999
283
1241
3041
2119
2163
1944
2338
1416
2866
2259
2023
2615
1667
4160
5365
6229
3296
9046
479
3283
6242
4411
5114
3917
5608
2502
7023
5465
4060
6361
3164
41.2
47.9
48.1
39
44.2
59.1
37.8
48.7
48
42.3
49.6
41.7
56.6
40.8
41.3
49.8
41.1
52.7
No
. E
ve
nt
No
. P
ati
en
t
Ra
te 
(%
)
No
. E
ve
nt
No
. P
ati
en
t
Ra
te 
(%
)
0.50 0.75 1.00 1.25 1.50
CRT Better ICD Better
The p-value is from the test statistic for testing the interaction between the device and any subgroup variable. The rate is the event rate.
The Forest plot depicts multivariable adjusted (for all covariates, including chronic kidney disease) subgroup analyses relating the association between
device type (CRT-D vs. ICD alone), baseline characteristics, and the primary outcome of HF hospitalization or death. LBBB ¼ left bundle branch block;
NYHA ¼ New York Heart Association; other abbreviations as in Figure 1.
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2627measures of quality of life, functional status, and
symptom burden. This study utilized registry data
linked to administrative claims, and as such, the re-
sults may be adversely affected by inaccuracies in
data collection and coding. The creatinine values
used to calculate GFR were the last known values,
and although we excluded patients implanted during
an acute hospitalization, we cannot be certain that all
creatinine values were truly representative of pa-
tients’ baseline renal function. We did not have ac-
cess to follow-up laboratory analyses and thus could
not assess the relation between CRT-D use and
changes in renal function that could be clinically
relevant. Our study was limited to CKD patients who
were felt suitable for ICD implantation and may not
be generalizable to all CKD patients. There were fewer
patients with stage 4 and 5 CKD (compared with stage
3), and as such, analyses of stage 4 and 5 patients
were not powered to detect associations between
device type and certain outcomes in our subgroupanalyses. CRT-D was more often implanted at
higher-volume CRT centers that may have superior
medication management and outpatient follow-up;
however, the ICD Registry includes a wide variety of
sites, and we have adjusted for multiple site and
physician-related factors. Finally, our study
compared CRT-D versus ICD and thus we are unable
to determine the relative efﬁcacy of CRT-D compared
with CRT with pacemaker or to medical management
because patients managed without a deﬁbrillator are
not enrolled in the ICD Registry.
CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS.
Current guidelines recommend CRT without partic-
ular regard to kidney function (26). However, in-
dividuals with advanced CKD may be less likely
to receive CRT (12). The reasons for decreased CRT
use are likely multifactorial, including concerns
regarding increased risk of complications, decreased
likelihood of clinical response, and increased
competing causes of morbidity and mortality. Taken
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: CRT-D is associated with a
lower risk of heart failure hospitalization or death
among patients with stages 3 to 5 chronic kidney
disease, including those on dialysis, than management
with deﬁbrillators alone.
TRANSLATIONAL OUTLOOK: Future studies
should address the impact of CRT on such patient-
oriented outcomes as quality of life, functional
status, and mental health.
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2628in sum, the results from this study support the use of
CRT independent of kidney function (particularly in
LBBB patients) and similarly support the existing
guideline recommendations. Importantly, CRT im-
plantation appears to be safe in individuals with
advanced CKD.
Future prospective studies on this topic are needed
to conﬁrm these results. Prospective studies
measuring patient-centered outcomes are likely to
improve our understanding of how CRT inﬂuences
quality of life, functional status, and HF symptoms in
CKD patients. This valuable information would allow
for vast improvements in patient education and the
shared decision-making process regarding whether
or not to pursue CRT in this highly comorbid, symp-
tomatic population.
CONCLUSIONS
In a nationally representative cohort of older
patients with symptomatic HF and moderate to se-
vere CKD, CRT-D was associated with a reduction in
the risk of HF hospitalization and mortality, in the
context of acceptable complication rates. Theseresults should be conﬁrmed by prospective ran-
domized studies.
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